[
    [
        {
            "time": "2018-06-20",
            "original_text": "复星医药：子公司逾4亿元收购迪会信28%股权",
            "features": {
                "keywords": [
                    "复星医药",
                    "收购",
                    "迪会信",
                    "股权"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "复星医药：子公司逾4亿元收购迪会信28%股权",
                "Correlation": 10,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-06-20",
            "original_text": "复星医药：顺应供给侧改革，用心做好药",
            "features": {
                "keywords": [
                    "复星医药",
                    "供给侧改革",
                    "好药"
                ],
                "sentiment_score": 0.8,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "复星医药：顺应供给侧改革，用心做好药",
                "Correlation": 8,
                "Sentiment": 6,
                "Importance": 5,
                "Impact": 4,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 5,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-06-20",
            "original_text": "国务院常务会确定加快已在境外上市新药审批（股）",
            "features": {
                "keywords": [
                    "国务院",
                    "新药审批",
                    "政策"
                ],
                "sentiment_score": 0.9,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "国务院常务会确定加快已在境外上市新药审批（股）",
                "Correlation": 6,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 3,
                "Market_Scope": 9,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-06-21",
            "original_text": "21日利好公告：复星医药逾4亿元收购迪会信28%股权(更新中)",
            "features": {
                "keywords": [
                    "复星医药",
                    "收购",
                    "迪会信",
                    "股权"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "21日利好公告：复星医药逾4亿元收购迪会信28%股权(更新中)",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 8,
                "Duration": 6,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-06-19",
            "original_text": "【金融工程】唐军、潘琨（联系人）：中泰金工事件驱动周报主营产品涨价及冷门股效应-20180619",
            "features": {
                "keywords": [
                    "金融工程",
                    "主营产品涨价",
                    "冷门股效应"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "金融"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "【金融工程】唐军、潘琨（联系人）：中泰金工事件驱动周报主营产品涨价及冷门股效应-20180619",
                "Correlation": 3,
                "Sentiment": 5,
                "Importance": 4,
                "Impact": 3,
                "Duration": 4,
                "Entity_Density": 2,
                "Market_Scope": 6,
                "Time_Proximity": 3,
                "Headline_Structure": 5,
                "Source_Recency": 2
            }
        },
        {
            "time": "2018-06-20",
            "original_text": "PD-1抗体药物获准进口 国内市场竞争将更趋激烈",
            "features": {
                "keywords": [
                    "PD-1抗体",
                    "进口",
                    "市场竞争"
                ],
                "sentiment_score": -0.5,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "PD-1抗体药物获准进口 国内市场竞争将更趋激烈",
                "Correlation": 7,
                "Sentiment": 5,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 4,
                "Market_Scope": 9,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-06-20",
            "original_text": "医药周报: 推荐医保目录和一致性评价政策下估值合理、业绩和成长确定表现的",
            "features": {
                "keywords": [
                    "医保目录",
                    "一致性评价",
                    "政策",
                    "估值合理",
                    "业绩",
                    "成长"
                ],
                "sentiment_score": 0.8,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "医药周报: 推荐医保目录和一致性评价政策下估值合理、业绩和成长确定表现的",
                "Correlation": 5,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 3,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 5,
                "Source_Recency": 7
            }
        }
    ]
]